Local, language-minority and Latin American news sites join the Trust Project
PACIFICA, Calif., April 29, 2025 /CNW/ -- As we approach World Press Freedom Day, two news organizations in Latin America, one in Canada and one in the United States have earned the Trust Mark, which indicates their commitment to independent journalism of public value. After months of training, they have structured integrity throughout their work by applying the 8 Trust Indicators®.
The public will now hear, see and read about their journalists, where they got their information and what policies guide them. Among other disclosures, they will see opinion clearly separated from news, find corrections for any errors easily, and as the Trust Project deepens its attention to ethical use of artificial intelligence, gain a concrete understanding of each site's use of AI tools in newsgathering and production.
The Trust Project ® welcomes The Beacon, a growing force in Kansas and Missouri that fills critical news gaps and provides free news stories to other publishers; BioBioChile, which explores issues throughout Chile with the country's cultural, social and economic diversity in mind; El Diario, which explains the news in Venezuela with depth to support public discourse; and Le Courrier de la Nouvelle-Écosse, which serves the French-speaking minority in Nova Scotia. El Diario and BioBioChile are the first news organizations in their countries to participate. All made substantial upgrades to their standards and overall transparency. The public can easily see why their news is worth attention and trust – and hold them accountable.
"We work closely with news organizations globally to strengthen the clear value of their journalism to the public," said Trust Project founder and CEO Sally Lehrman. "We're proud of the many changes these incoming news partners made to earn well-deserved confidence through transparency and integrity, including in their use of AI."
More than 300 fully approved Trust Project news partners continue to build integrity into every aspect of their journalism: newsgathering; news presentation online, in audio and video; even in their business operations. When news outlets complete the Trust Indicators in policy and practice, they earn the Trust Mark.
The Trust Indicators® empower people to stay informed and thrive by making it easy to choose news with confidence.
The Trust Project is grateful to our funders, who support our research on trust, workshops and training, and ongoing work with Trust Project Network sites and others to build a trustworthy news ecosystem the public values. Learn about making a donation here.
About the Trust Project:
8 Trust Indicators®, a collaborative, journalism-generated and proven standard that helps both regular people and algorithms easily assess the authority and integrity of news. Polices and standards are shaped through user research and enforced independently from the project's funding sources. For more, visit: https://thetrustproject.org/faq/.
Media Contact:
Jessica Sterling, 650-728-8211
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
7 hours ago
- Cision Canada
VITALITY ANNOUNCES FIRST QUARTER RESULTS
TSXV Trading Symbol: VPI VANCOUVER, BC, June 30, 2025 /CNW/ - Vitality Products Inc. (TSXV: VPI) (the "Company" or "Vitality"), a manufacturer, marketer and distributor of premium vitamins and supplements, is pleased to report its financial results for the first quarter ended April 30, 2025. Year-Over-Year Financial Highlights: Sales increased 19% Gross Margin of 71% Net Loss decreased 92% Sales of the Company's premium natural health products for the three months ended April 30, 2025 increased 19% to $234,418 (2024 - $196,879). The Company's gross margin on its sales for the three months ended April 30, 2025 was $167,343 or 71% of sales (2024 - $141,662 or 72% of sales) as the Company continues to have strong gross margins due to the uniqueness of its natural health products. The financial performance of the Company for the three months ended April 30, 2025 is highlighted by a 92% reduction in net loss as the Company continues to make significant strides towards its goal of profitability on a quarterly basis. The financial results of the Company for the three months ended April 30, 2025 show a net loss of $3,219 or $0.00 per share compared to a net loss of $40,455 or $0.00 per share for the same period last year. The Company's general selling expenses for the three months ended April 30, 2025 decreased to $28,281 (2024 - $40,364). The Company's general and administrative expenses for the three months ended April 30, 2025 increased to $138,438 (2024 - $137,871). The Company is focused on expanding distribution and growing sales in Canada and the United States while maintaining its overall operating efficiencies. During the three months ended April 30, 2025, Vitality exhibited at two industry tradeshows. The Company sold its natural health products directly to consumers at the Vancouver Wellness Show in February 2025. The Company met with current and prospective retailer buyers at CHFA NOW in Vancouver in April 2025. The Company's condensed interim financial statements and management's discussion and analysis for the three months ended April 30, 2025 and 2024 are available on SEDAR+ at About Vitality VITALITY ® is an award-winning line of clean vitamins and supplements, marketed to natural health retailers and health and wellness conscious consumers. Manufactured in Canada and currently sold in natural health stores and online, the products are non-GMO and third party tested for quality. Following the proven success of the line through repeat orders and same store sales growth, the Company is focused on expanding distribution and growing sales in-store and online; evaluating, researching and developing new products for future distribution; and exploring new markets for its products. To view our products, visit: On behalf of the Board of VITALITY PRODUCTS INC. "Cheryl A. Grant" (signed) __________________________________ Cheryl A. Grant, President & CEO Forward-Looking Information Information set forth in this news release involves forward-looking statements. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address a company's expected future business and financial performance, and often contain words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: risks associated with marketing and sale of securities; the need for additional financing; reliance on key personnel; the potential for conflicts of interest among certain officers or directors with certain other projects; and the volatility of common share price and volume. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and except as required by law, the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Investors are cautioned against attributing undue certainty to forward-looking statements. THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS NEWS RELEASE REPRESENTS THE EXPECTATIONS OF THE COMPANY AS OF THE DATE OF THIS NEWS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE THE COMPANY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE SECURITIES LEGISLATION.
Cision Canada
13 hours ago
- Cision Canada
ALLIANCE CONNECTION CELEBRATES 15 YEARS OF SHAPING THE FUTURE OF TRAVEL
Launches SPARK® at Landmark Industry Event Bringing Together Hospitality's Boldest Visionaries MIAMI, /CNW/ -- Alliance Connection, a leading travel marketing and communications agency specializing in the Caribbean and Mexico, marked a pivotal moment in its journey with the official launch of SPARK®, a new strategic solution built to ignite the future of travel by delivering trendcasting insights, immersive workshops, ready-to-use marketing playbooks, guest experience blueprints, and opportunities for forward-thinking collaboration. The product debut coincided with the agency's 15th anniversary celebration, an unforgettable evening that brought together some of the most respected minds in hospitality, representing over 200 resorts across 16 destinations. In the room were the driving forces behind many of the industry's most influential brands, including Nickelodeon Hotels & Resorts, Margaritaville Island Reserve® Collection, Sandals® and Beaches® Resorts, and more. Notable attendees included Marilyn Cairo of Classic Vacations; Debbie-Ann White and Liz Kaiser of Unique Vacations; Frank Corzo of Club Med; Amy Zocchi, Chelsea Commodari, and Lindsay Pullen of Hyatt's Inclusive Collection; and Irene Barbosa and Francia Haces of Karisma Hotels & Resorts, underscoring the depth of expertise and industry-shaping influence present. Also in attendance were longtime industry icons who helped shape Alliance Connection's story from the very beginning, including Armando "Mandy" Chomat, widely regarded as a visionary architect of the all-inclusive model; Frank Maduro, who played a pivotal role in launching the all-inclusive Hard Rock Hotels and UNICO 20°87° brands; and Ash Tembe of AIC Hotel Group, whose bold leadership has redefined how resorts connect with travelers. "This celebration was more than a product launch. It's a tribute to the people and partnerships that helped get us here, and a powerful step toward where we're going next," said Melissa Mango, President and Founder of Alliance Connection. "To have the brightest, most respected minds in tourism in the same room, people who've shaped brands, inspired innovation, and supported us through every stage, is incredibly meaningful. We are grateful to build the future of travel alongside them." At the event, SPARK® was unveiled as Alliance Connection's cutting-edge platform designed specifically for travel marketers, agents, resort owners, and hoteliers to transform big ideas into real-world results. SPARK® empowers teams with exclusive trend reports, ready-to-launch campaign toolkits, and strategic advisory sessions that go beyond inspiration by delivering clear, actionable strategies to ignite brand visibility, accelerate time-to-market, and create standout guest experiences. By combining proprietary trendcasting, immersive programming, and skill-based training, SPARK® helps resorts lead industry conversations, sharpen their marketing execution, and convert bold concepts into bookings. It complements Alliance Connection's existing suite of services, including transformative PR, influencer marketing, brand partnerships, and experiential activations to fuel every stage of a brand's journey. "This moment wasn't just about looking back, it was about building what's next," added Madison Salyer, Executive Director of Alliance Connection. "With SPARK®, we're laying the foundation for future-forward marketing that empowers our partners to move faster, think bigger, and stay ahead of what's next in travel. We will always be innovators, but what makes this work truly powerful is the community we're privileged to create alongside. From trendcasting to immersive experiences and next-gen brand collaborations, SPARK® is just the beginning. We're all in on all-inclusive, and we're just getting started." Guests previewed the first proprietary SPARK® tools and experienced activations including: A playful aerial and bungee fitness experience that encouraged guests to shake off stress, reset their energy, and get into an expansive mindset before coming to the table with big ideas The Bold Tank™, Alliance Connection's new innovation lab, where teams use SPARK® Prompt Cards to co-create, collaborate across divisions, and pitch breakthrough marketing ideas to shape the future of travel A Vibe & Vision corner that inspired brand creativity through soundscapes guests could pair to their brand ethos and hands-on vision board creation, blending audio and visual storytelling to spark clarity, imagination, and connection DJ Diego Ciaramella blended vinyl and digital beats, while celebrity tarot reader Sisther Pravia offered a glimpse into the future of travel through intuitive readings, offering a snapshot of Alliance Connection's Artist in Residence program, which showcases influential experts to create unforgettable travel experiences for guests The 15-Year Anniversary Edition of the beloved AC Faves Gifting Suite featured curated favorites from inspiring partners like Honest, Sugarfina, Tory Burch, Able, and Silver Spoon Desserts, many of them women-founded brands with bold stories of purpose and passion An "Under the Influence" mixology lab with a cocktail menu inspired by top influencers and content creators in the AC Creator Community™ Every year, Alliance Connection's campaigns reach over 150 million U.S. consumers through a powerful blend of integrated marketing and communications. The agency also boasts an average 47:1 campaign ROI, and a 12.7-year client retention rate, one of the highest in the industry, while continuing to lead at the intersection of culture, creativity, and commerce for travel and tourism across the Caribbean and Mexico. Building on these unrivaled results, Alliance Connection drives measurable impact through strategic brand partnerships, immersive experiences, and media-worthy moments that resonate with today's travelers. As the agency looks ahead to the next 15 years, its mission remains rooted in innovation, collaboration, and gratitude for the hospitality professionals who make the work meaningful. To explore SPARK®, learn more about Alliance Connection, or inquire about collaborating with the team, visit See photos here. About Alliance Connection Alliance Connection is a bold marketing and communications agency built exclusively for the travel, tourism, and hospitality industries with a specialty in all-inclusive resorts across the Caribbean and Mexico. For over 15 years, the agency has helped some of the region's most iconic resort brands turn stories into bookings through integrated strategies that fuse PR, influencer marketing, brand partnerships, and experiential activations. With proprietary programs like SPARK®, a campaign reach of over 150 million U.S. consumers annually, and more than 1,400 successful brand campaigns, Alliance Connection delivers measurable impact. From trendcasting and content ecosystems to co-branded experiences that convert, the agency helps clients move travelers from awareness to action. As the powerhouse behind paradise, Alliance Connection is the engine behind the region's most unforgettable resort all-inclusive brands like the all-inclusive Hard Rock Hotels, Meliá Hotels, Hyatt's Inclusive Collection, Nickelodeon Hotels & Resorts, Margaritaville Island Reserve® by Karisma, and AIC's Hotel Group - Nobu Hotels, UNICO, and more.
Cision Canada
19 hours ago
- Cision Canada
Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy
SAN DIEGO and CALGARY, Alberta, June 30, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Andrew Aromando as Chief Business Officer. Mr. Aromando most recently served as Chief Operating Officer at Ambrx Biopharma, where his contributions were instrumental in the $2 billion acquisition of the San Diego-based biotech by Johnson & Johnson. In his role at Oncolytics, Mr. Aromando will be responsible for leading global business development. He will also be directly involved with developing corporate, clinical and regulatory strategies. Among his key priorities will be optimizing the value of the Company's expansive suite of promising clinical data for pelareorep in multiple tumor types, including pancreatic, breast, and anal cancers. "Andrew's experience will be invaluable as we pursue aggressive clinical and business development strategies to maximize the value of pelareorep on an accelerated timeline," said Jared Kelly, Chief Executive Officer of Oncolytics. "He is a proven industry leader with a successful track record of navigating complex transactions and partnerships and an outstanding addition to our executive team." Mr. Aromando added, "I'm thrilled to join Oncolytics at such a pivotal moment in its evolution. With promising data in difficult-to-treat cancers and a compelling body of clinical evidence in over 1,100 patients, I believe the Company is uniquely positioned to deliver meaningful value to patients and other stakeholders in the near term." Mr. Aromando has over 30 years of experience in the life sciences industry. He has served more than 20 years in C-level positions at leading oncology-focused biopharma companies and global service providers. His senior executive roles at these companies were centered on strategic planning, corporate development, portfolio optimization, and product commercialization. He earned his BA from The College of New Jersey and MA from Rutgers University. As a material inducement to Mr. Aromando's appointment as Chief Business Officer, and in accordance with NASDAQ Listing Rule 5635(c)(4), Mr. Aromando has been awarded an initial stock option grant exercisable for 750,000 shares with an exercise price of CAD$0.93, vesting equally over three years with a term of 5 years from the date of grant. The Company also granted Mr. Aromando 500,000 restricted stock units, which vest upon the Company entering into a definitive agreement for certain transactions providing for the acquisition of the Company or the exclusive license of pelareorep. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For more about Oncolytics, please visit: or follow the company on social media on LinkedIn and on X @ oncolytics. This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; our plans, objectives and strategies; our focus on advancing pelareorep into registration enabling studies; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws. Company Contact Jon Patton Director of IR & Communication [email protected] Investor Relations for Oncolytics Mike Moyer LifeSci Advisors +1-617-308-4306 [email protected] Media Contact for Oncolytics Owen Blaschak LifeSci Communications [email protected] SOURCE Oncolytics Biotech® Inc.
